- Home
- REKR vs CRDF Comparison
REKR vs CRDF Comparison
Compare REKR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REKR
- CRDF
- Stock Information
- Founded
- REKR 2017
- CRDF 1999
- Country
- REKR United States
- CRDF United States
- Employees
- REKR N/A
- CRDF N/A
- Industry
- REKR Telecommunications Equipment
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REKR Telecommunications
- CRDF Health Care
- Exchange
- REKR Nasdaq
- CRDF Nasdaq
- Market Cap
- REKR 151.6M
- CRDF 152.3M
- IPO Year
- REKR N/A
- CRDF N/A
- Fundamental
- Price
- REKR $2.31
- CRDF $2.24
- Analyst Decision
- REKR
- CRDF Strong Buy
- Analyst Count
- REKR 0
- CRDF 5
- Target Price
- REKR N/A
- CRDF $11.10
- AVG Volume (30 Days)
- REKR 9.0M
- CRDF 762.1K
- Earning Date
- REKR 11-13-2025
- CRDF 10-29-2025
- Dividend Yield
- REKR N/A
- CRDF N/A
- EPS Growth
- REKR N/A
- CRDF N/A
- EPS
- REKR N/A
- CRDF N/A
- Revenue
- REKR $45,380,000.00
- CRDF $545,000.00
- Revenue This Year
- REKR $10.03
- CRDF N/A
- Revenue Next Year
- REKR $24.80
- CRDF N/A
- P/E Ratio
- REKR N/A
- CRDF N/A
- Revenue Growth
- REKR 7.05
- CRDF N/A
- 52 Week Low
- REKR $0.62
- CRDF $1.90
- 52 Week High
- REKR $3.42
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- REKR 48.73
- CRDF 49.28
- Support Level
- REKR $2.56
- CRDF $2.20
- Resistance Level
- REKR $2.60
- CRDF $2.36
- Average True Range (ATR)
- REKR 0.25
- CRDF 0.10
- MACD
- REKR -0.09
- CRDF 0.00
- Stochastic Oscillator
- REKR 5.93
- CRDF 49.98
About REKR Rekor Systems Inc.
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which a majority of its revenue comes from the United States.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.